Breast cancer · 7 regimens
Cost vs Efficacy · 6 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
nab-Paclitaxel monotherapy Variant #01 | — | R 45 710 | 28d | ~5.6 mo | ~16.8 mo | ~7 | ~R 319 969 PFS proxy · indirect | 12 |
Eribulin monotherapy Variant #01 | — | R 24 243 | 21d | ~4.1 mo | ~13.1 mo | ~6 | ~R 145 460 PFS proxy · indirect | 22 |
Ixabepilone monotherapy Variant #01 | — | R 14 725 | 21d | — | ~7.5 mo | — | — | 1 |
Gemcitabine monotherapy Variant #20 | — | R 14 213 | 56d | ~4.6 mo | ~11.0 mo | ~3 | ~R 42 639 PFS proxy · indirect | 16 |
Paclitaxel monotherapy Variant #46 | — | R 2 220 | 28d | ~6.4 mo | ~16.8 mo | ~7 | ~R 15 537 PFS proxy · indirect | 28 |
Vinorelbine monotherapy Variant #01 | — | R 583 | 21d | ~4.0 mo | ~10.1 mo | ~6 | ~R 3 500 PFS proxy · indirect | 18 |
Docetaxel monotherapy N/A - secondary systemic drug | — | R 243 | 28d | ~8.0 mo | ~11.5 mo | ~9 | ~R 2 188 PFS proxy · indirect | 11 |
7 of 7 regimens shown